Daniel Brennan
Equibles does not estimate personal net worth.
About Daniel Brennan
Earlier roles on record: CFO at Boston Scientific Corp (BSX) until June 29, 2025. Boston Scientific Corp reported in an 8-K filed April 23, 2025 that Daniel Brennan retired as Executive Vice President and Chief Financial Officer, effective June 29, 2025. The proxy statement of Boston Scientific Corp reports total compensation of $6,282,896 for Daniel Brennan in fiscal 2025, including a base salary of $660,990. Disclosed compensation is on record for 9 fiscal years. Daniel Brennan has spoken on 12 earnings calls across 1 company, most recently for Boston Scientific Corp on April 23, 2025. The companies whose calls Daniel Brennan spoke on are classified in the Healthcare sector.
“On April 23, 2025, Boston Scientific Corporation (the "Company") announced that Daniel J. Brennan has decided to retire from his role as Executive Vice President and Chief Financial Officer of the Company effective as of June 29, 2025, and that Jonathan Monson, who currently serves as Senior Vice President, Investor Relations, has been promoted to Executive Vice President and Chief Financial Officer of the Company effective as of June 30, 2025.”
Daniel Brennan on recent calls
“First quarter consolidated revenue of $4.663 billion represents 20.9% reported growth versus first quarter 2024 and includes a 130 basis point headwind from foreign exchange, which was unfavorable versus our expectations.”
“Endoscopy sales grew 8% operationally and 7% in the fourth quarter organically. On a full-year basis, we grew 9% operationally and 8% organically.”
“Third quarter 2024 consolidated revenue of $4,209 million represents 19.4% reported growth versus third quarter of 2023 and includes a 10 basis point headwind from foreign exchange, which was favorable versus our expectations.”
“Second quarter 2024 consolidated revenue of $4.120 billion represents 14.5% reported growth versus second quarter 2023 and includes a 160 basis point headwind from foreign exchange, which was slightly unfavorable versus our expectations.”
“First quarter 2024 consolidated revenue of $3.856 billion represents 13.8% reported growth versus first quarter 2023 and includes a 120 basis point headwind from foreign exchange, in line with our expectations.”
Affiliation history
-
Start not stated–2025-06-29
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Boston Scientific Corp (BSX) | Former Executive Vice President and Chief Financial Officer | $660,990 | $6,282,896 |
| 2024 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $843,146 | $6,687,005 |
| 2023 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $801,528 | $5,829,147 |
| 2022 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $765,959 | $5,252,206 |
| 2021 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $692,183 | $4,429,827 |
| 2020 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $560,422 | $3,668,993 |
| 2019 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $655,437 | $4,031,286 |
| 2018 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $621,637 | $3,665,825 |
| 2017 | Boston Scientific Corp (BSX) | Executive Vice President and Chief Financial Officer | $593,194 | $3,632,769 |